Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4621197 | 1.00 | RAB9A (0.35) | RAB9A | |
| SCHEMBL4619347 | 1.00 | RAB9A (0.35) | RAB9A | |
| SCHEMBL4620679 | 1.00 | RAB9A (0.35) | RAB9A | |
| SCHEMBL4620112 | 1.00 | — | — | |
| SCHEMBL4621327 | 0.97 | — | — | |
| SCHEMBL919947 | 0.88 | — | — | |
| SCHEMBL30843939 | 0.85 | RAB9A (0.43) | RAB9A | |
| SCHEMBL3618326 | 0.85 | RAB9A (0.43) | RAB9A | |
| SCHEMBL29409450 | 0.85 | RAB9A (0.43) | RAB9A | |
| SCHEMBL5607915 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756271-B1 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM 2,2-DISUBSTITUTED EPOXIDES | CSIR (ZA) | 2015-12-09 | — | — | EP | disclosed |
| EP-1753862-B1 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM MESO-EPOXIDES | CSIR (ZA) | 2015-11-18 | — | — | EP | disclosed |
| US-20080286832-A1 | Methods for Obtaining Optically Active Epoxides and Vicinal Diols From 2,2-Disubstituted Epoxides | COUNCIL FOR SCIENTIFIC AND INDUSTRIAL RESEARCH (ZA) | 2008-11-20 | — | — | US | disclosed |
| US-20080213833-A1 | Methods for Obtaining Optically Active Glycidyl Ethers and Optically Active Vicinal Diols from Racemic Substrates | OXRANE (UK) LTD. (GB) | 2008-09-04 | — | — | US | disclosed |
| US-20080199912-A1 | Methods for Obtaining Optically Active Epoxides and Diols from 2,3-Disubstituted and 2,3-Trisubstituted Epoxides | OXYRANE (UK) LTD. (GB) | 2008-08-21 | — | — | US | disclosed |
| EP-1896597-A2 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND DIOLS FROM 2,3-DISUBSTITUTED AND 2,3-TRISUBSTITUTED EPOXIDES | CSIR (ZA) | 2008-03-12 | — | — | EP | disclosed |
| EP-1885849-A2 | METHODS FOR OBTAINING OPTICALLY ACTIVE GLYCIDYL ETHERS AND OPTICALLY ACTIVE VICINAL DIOLS FROM RACEMIC SUBSTRATES | Oxyrane UK Limited (GB) | 2008-02-13 | — | — | EP | disclosed |
| US-20070275448-A1 | Methods For Obtaining Optically Active Epoxides And Vicinal Diols From Meso-Epoxides | CSIR (ZA) | 2007-11-29 | — | — | US | disclosed |
| WO-2007069079-A2 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND DIOLS FROM 2,3-DISUBSTITUTED AND 2,3-TRISUBSTITUTED EPOXIDES | CSIR (US) | 2007-06-21 | — | — | WO | disclosed |
| EP-1756271-A2 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM 2,2-DISUBSTITUTED EPOXIDES | CSIR (ZA) | 2007-02-28 | — | — | EP | disclosed |
| EP-1753862-A2 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM MESO-EPOXIDES | CSIR (ZA) | 2007-02-21 | — | — | EP | disclosed |
| WO-2006109198-A2 | METHODS FOR OBTAINING OPTICALLY ACTIVE GLYCIDYL ETHERS AND OPTICALLY ACTIVE VICINAL DIOLS FROM RACEMIC SUBSTRATES | OXYRANE UK LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2005100587-A2 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM 2,2-DISUBSTITUTED EPOXIDES | CSIR (ZA) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005100578-A2 | METHODS FOR OBTAINING OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM MESO-EPOXIDES | CSIR (ZA) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080199912-A1 | Methods for Obtaining Optically Active Epoxides and Diols from 2,3-Disubstituted and 2,3-Trisubstituted Epoxides | EPHX2, ERG28, EPHX1 | RAB9A 3483/4885 |
| US-20080213833-A1 | Methods for Obtaining Optically Active Glycidyl Ethers and Optically Active Vicinal Diols from Racemic Substrates | GALE, DERA, GNE | RAB9A 3108/4885 |
| US-20070275448-A1 | Methods For Obtaining Optically Active Epoxides And Vicinal Diols From Meso-Epoxides | EPHX2, EPHX1, DHODH | RAB9A 2930/4885 |
| US-20080286832-A1 | Methods for Obtaining Optically Active Epoxides and Vicinal Diols From 2,2-Disubstituted Epoxides | EPHX2, ERG28, DERA | RAB9A 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.